SCHEDULE 13G/A: Frazier Life Sciences Funds Disclose Passive Ownership in ORIC Pharmaceuticals
Beneficial Ownership Disclosure
Frazier Life Sciences and affiliated entities have filed an amended Schedule 13G, disclosing their passive beneficial ownership in ORIC Pharmaceuticals, Inc. common stock as of March 31, 2025.
Summary
- Frazier Life Sciences Public Fund, L.P. and its related entities (FHMLSP, L.P. and FHMLSP, L.L.C.) collectively beneficially own 605,554 shares of ORIC Pharmaceuticals, Inc. common stock, representing 0.9% of the class.
- Frazier Life Sciences Public Overage Fund, L.P. and its related entities (FHMLSP Overage, L.P. and FHMLSP Overage, L.L.C.) collectively beneficially own 416,494 shares, representing 0.6% of the class.
- Frazier Life Sciences X, L.P. and its related entities (FHMLS X, L.P. and FHMLS X, L.L.C.) collectively beneficially own 129,479 shares, representing 0.2% of the class.
- Frazier Life Sciences XI, L.P. and its related entities (FHMLS XI, L.P. and FHMLS XI, L.L.C.) collectively beneficially own 258,666 shares, representing 0.4% of the class.
- Individual members associated with these funds, James N. Topper and Patrick J. Heron, each report shared beneficial ownership of 1,410,193 shares, equating to 2.0% of the class.
- Albert Cha and James Brush each report shared beneficial ownership of 1,022,048 shares, equating to 1.4% of the class.
- Daniel Estes reports shared beneficial ownership of 258,666 shares, equating to 0.4% of the class.
- The percentages are calculated based on 71,026,825 shares of Common Stock outstanding as of February 4, 2025, as reported in ORIC Pharmaceuticals' Annual Report on Form 10-K filed on February 18, 2025.
- The filing certifies that the securities were not acquired and are not held for the purpose of changing or influencing the control of ORIC Pharmaceuticals, Inc.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently lead to a positive or negative sentiment. It is a neutral, compliance-driven filing.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of passive beneficial ownership by investment funds in a publicly traded pharmaceutical company. It does not provide specific insights into ORIC Pharmaceuticals' operational performance or strategic direction, but rather reflects an investment position by Frazier Life Sciences funds.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant passive ownership stakes by institutional investors, which can be a signal of investor confidence, though the percentages are relatively small.
Key Dates
| Date | Description |
|---|---|
| 2025-02-04 | Date on which 71,026,825 shares of Common Stock were outstanding, as per Issuer's Form 10-K. |
| 2025-02-18 | Date of filing of Issuer's Annual Report on Form 10-K with the SEC. |
| 2025-03-31 | Date of event which requires the filing of this Schedule 13G statement. |
| 2025-05-15 | Date of filing for this Schedule 13G Amendment No. 1. |
Keywords
ORIC Pharmaceuticals, Frazier Life Sciences, Schedule 13G, Beneficial Ownership, SEC Filing, Common Stock, Institutional Investor, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.